Overview

Integrating Geriatric Assessment and Genetic Profiling to Personalize Therapy Selection in Older Adults With Acute Myeloid Leukemia

Status:
Recruiting

Trial end date:
2023-07-07

Target enrollment:

Participant gender:

Summary

This phase II trial of the impact of clinicogenetic risk-stratified management on outcomes of acute myeloid leukemia in older patients is to determine the rate of complete remission and mortality at 90 days in the entire cohort of older patients (≥60 years) with newly diagnosed acute myeloid leukemia, who receive clinicogenetic risk-stratified therapy allocation. Subjects will receive standard of care intensive or low-intensity induction based on cytogenetic and geriatric assessment-based risk stratification. Subjects will be evaluated for disease status, survival, quality of life and neurocognitive status for 90 days and then followed for a total of 2 years for survival data.

Phase:

Phase 2

Details

Lead Sponsor:

University of Nebraska

Collaborator:

National Cancer Institute (NCI)

Treatments:

Azacitidine
Cytarabine
Daunorubicin
Decitabine
Idarubicin
Venetoclax